A white paper has been submitted to the US Food and Drug Administration (FDA) as evidence that future osteoarthritis applications should be considered under one of their expedited programs for serious conditions. Osteoarthritis: A Serious Disease, auspiced by the Osteoarthritis Research Society International (OARSI) with substantial contributions from Australian experts, was submitted to the FDA late ...
White paper paints osteoarthritis as a serious disease
By Mardi Chapman
30 May 2017